Literature DB >> 2120438

TNF, soluble IL-2R and soluble CD-8 in Behçet's disease.

T F Akoğlu, H Direskeneli, H Yazici, R Lawrence.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2120438

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  10 in total

Review 1.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

Review 2.  Pathogenesis of Adamantiades-Behçet's disease.

Authors:  Christos C Zouboulis; Tobias May
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

3.  Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS).

Authors:  J Freysdottir; S Lau; F Fortune
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

4.  Immune and inflammatory gene expressions are different in Behçet's disease compared to those in Familial Mediterranean Fever.

Authors:  Filiz Türe Özdemir; Emel Ekşioğlu Demiralp; Sibel Z Aydın; Pamir Atagündüz; Tülin Ergun; Haner Direskeneli
Journal:  Eur J Rheumatol       Date:  2016-12-01

5.  Gene expression of tumour necrosis factor-alpha (TNF-alpha) and heat-shock protein (HSP) 70 in patients with Behçet's disease.

Authors:  Y Yamakawa; Y Sugita; Y Takahashi; T Yamakawa; S Tanaka; S Nakamura; J Fukushima; S Kawamoto; S Ohno; K Okuda
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

6.  Neutrophil adhesion to endothelial cells and factors affecting adhesion in patients with Behçet's disease.

Authors:  S Sahin; T Akoğlu; H Direskeneli; L S Sen; R Lawrence
Journal:  Ann Rheum Dis       Date:  1996-02       Impact factor: 19.103

7.  Anti-MHC autoimmunity in Behçet's disease: T cell responses to an HLA-B-derived peptide cross-reactive with retinal-S antigen in patients with uveitis.

Authors:  S Kurhan-Yavuz; H Direskeneli; N Bozkurt; Y Ozyazgan; T Bavbek; H Kazokoglu; E Eksioglu-Demiralp; G Wildner; M Diedrichs-Möhring; T Akoglu
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

8.  Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease.

Authors:  Nurşen Düzgün; Ergin Ayaşlioğlu; Hüseyin Tutkak; Olcay T Aydintuğ
Journal:  Rheumatol Int       Date:  2003-11-05       Impact factor: 2.631

9.  Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1.

Authors:  Bharati Sanjanwala; Monia Draghi; Paul J Norman; Lisbeth A Guethlein; Peter Parham
Journal:  J Immunol       Date:  2008-11-01       Impact factor: 5.422

10.  Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet's disease.

Authors:  H Direskeneli; G Keser; D D'Cruz; M A Khamashta; T Akoğlu; H Yazici; S Yurdakul; V Hamuryudan; S Ozgün; A J Goral
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.